The tumor promoter and NF-κB modulator Bcl-3 regulates splenic B cell development

Journal of Immunology

Volumn 191, Issue 12, 2013, Pages 5984-5992

  Zhang, Xiaoren ^a,b   Paun, Andrea ^a   Claudio, Estefania ^a   Wang, Hongshan ^a   Siebenlist, Ulrich ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROTEIN BCL 3;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL COUNT; CELL FATE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; ENZYME REGULATION; FOLLICULAR B LYMPHOCYTE; GENE OVEREXPRESSION; MARGINAL ZONE B LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLEEN;

EID: 84890412404     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300611     Document Type: Article

References (49)

1. Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132: 344-362.
2. Siebenlist, U., K. Brown, and E. Claudio. 2005. Control of lymphocyte development by nuclear factor-kappaB. Nat. Rev. Immunol. 5: 435-445.
3. Ohno, H., G. Takimoto, and T. W. McKeithan. 1990. The candidate protooncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60: 991-997.
4. Nishikori, M., Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno. 2003. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101: 2789-2796.
5. Ohno, H., S. Doi, K. Yabumoto, S. Fukuhara, and T. W. McKeithan. 1993. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia 7: 2057-2063.
6. Ohno, H., M. Nishikori, Y. Maesako, and H. Haga. 2005. Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma. Int. J. Hematol. 82: 397-405.
7. Rassidakis, G. Z., M. P. Oyarzo, and L. J. Medeiros. 2003. BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood 102: 1146-1147.
8. Brenne, A. T., U. M. Fagerli, J. D. Shaughnessy, Jr., T. K. Våtsveen, T. B. Rø, H. Hella, F. Zhan, B. Barlogie, A. Sundan, M. Børset, and A. Waage. 2009. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur. J. Haematol. 82: 354-363.
9. Canoz, O., G. Z. Rassidakis, J. H. Admirand, and L. J. Medeiros. 2004. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod. Pathol. 17: 911-917.
10. Ibrahim, H. A., F. Amen, A. G. Reid, and K. N. Naresh. 2011. BCL3 rearrangement, amplification and expression in diffuse large B-cell lymphoma. Eur. J. Haematol. 87: 480-485.
11. Maldonado, V., and J. Melendez-Zajgla. 2011. Role of Bcl-3 in solid tumors. Mol. Cancer 10: 152.
12. Kashatus, D., P. Cogswell, and A. S. Baldwin. 2006. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 20: 225-235.
13. Rocha, S., A. M. Martin, D. W. Meek, and N. D. Perkins. 2003. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol. Cell. Biol. 23: 4713-4727.
14. Westerheide, S. D., M. W. Mayo, V. Anest, J. L. Hanson, and A. S. Baldwin, Jr. 2001. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol. Cell. Biol. 21: 8428-8436.
15. Bassetti, M. F., J. White, J. W. Kappler, and P. Marrack. 2009. Transgenic Bcl-3 slows T cell proliferation. Int. Immunol. 21: 339-348.
16. Brocke-Heidrich, K., B. Ge, H. Cvijic, G. Pfeifer, D. Löffler, C. Henze, T. W. McKeithan, and F. Horn. 2006. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25: 7297-7304.
17. Nishikori, M., H. Ohno, H. Haga, and T. Uchiyama. 2005. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 96: 487-497.
18. Chilton, P. M., and T. C. Mitchell. 2006. CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen. Infect. Immun. 74: 4180-4189.
19. Franzoso, G., L. Carlson, T. Scharton-Kersten, E. W. Shores, S. Epstein, A. Grinberg, T. Tran, E. Shacter, A. Leonardi, M. Anver, et al. 1997. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 6: 479-490.
20. Pène, F., A. Paun, S. U. Sønder, N. Rikhi, H. Wang, E. Claudio, and U. Siebenlist. 2011. The IkB family member Bcl-3 coordinates the pulmonary defense against Klebsiella pneumoniae infection. J. Immunol. 186: 2412-2421.
21. Riemann, M., R. Endres, S. Liptay, K. Pfeffer, and R. M. Schmid. 2005. The IkappaB protein Bcl-3 negatively regulates transcription of the IL-10 gene in macrophages. J. Immunol. 175: 3560-3568.
22. Ruan, Q., S. J. Zheng, S. Palmer, R. J. Carmody, and Y. H. Chen. 2010. Roles of Bcl-3 in the pathogenesis of murine type 1 diabetes. Diabetes 59: 2549-2557.
23. Schwarz, E. M., P. Krimpenfort, A. Berns, and I. M. Verma. 1997. Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 11: 187-197.
24. Zhang, X., H. Wang, E. Claudio, K. Brown, and U. Siebenlist. 2007. A role for the IkappaB family member Bcl-3 in the control of central immunologic tolerance. Immunity 27: 438-452.
25. Kuwata, H., Y. Watanabe, H. Miyoshi, M. Yamamoto, T. Kaisho, K. Takeda, and S. Akira. 2003. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 102: 4123-4129.
26. Wessells, J., M. Baer, H. A. Young, E. Claudio, K. Brown, U. Siebenlist, and P. F. Johnson. 2004. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide- induced inflammatory responses in macrophages. J. Biol. Chem. 279: 49995-50003.
27. Carmody, R. J., Q. Ruan, S. Palmer, B. Hilliard, and Y. H. Chen. 2007. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 317: 675-678.
28. Elliott, S. F., C. I. Coon, E. Hays, T. A. Stadheim, and M. P. Vincenti. 2002. Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum. 46: 3230-3239.
29. Richard, M., J. Louahed, J. B. Demoulin, and J. C. Renauld. 1999. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood 93: 4318-4327.
30. Hövelmeyer, N., F. T. Wunderlich, R. Massoumi, C. G. Jakobsen, J. Song, M. A. Wörns, C. Merkwirth, A. Kovalenko, M. Aumailley, D. Strand, et al. 2007. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J. Exp. Med. 204: 2615-2627.
31. Keutgens, A., K. Shostak, P. Close, X. Zhang, B. Hennuy, M. Aussems, J. P. Chapelle, P. Viatour, A. Gothot, M. Fillet, and A. Chariot. 2010. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol. Cell. Biol. 30: 4006-4021.
32. Keutgens, A., X. Zhang, K. Shostak, I. Robert, S. Olivier, A. Vanderplasschen, J. P. Chapelle, P. Viatour, M. P. Merville, F. Bex, et al. 2010. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1. J. Biol. Chem. 285: 25831-25840.
33. Massoumi, R., K. Chmielarska, K. Hennecke, A. Pfeifer, and R. Fässler. 2006. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665-677.
34. Viatour, P., E. Dejardin, M. Warnier, F. Lair, E. Claudio, F. Bureau, J. C. Marine, M. P. Merville, U. Maurer, D. Green, et al. 2004. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol. Cell 16: 35-45.
35. Poljak, L., L. Carlson, K. Cunningham, M. H. Kosco-Vilbois, and U. Siebenlist. 1999. Distinct activities of p52/NF-kappa B required for proper secondary lymphoid organ microarchitecture: functions enhanced by Bcl-3. J. Immunol. 163: 6581-6588.
36. Allman, D., and S. Pillai. 2008. Peripheral B cell subsets. Curr. Opin. Immunol. 20: 149-157.
37. Meyer-Bahlburg, A., S. Becker-Herman, S. Humblet-Baron, S. Khim, M. Weber, G. Bouma, A. J. Thrasher, F. D. Batista, and D. J. Rawlings. 2008. Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood 112: 4158-4169.
38. Wong, J. K., M. C. Strain, R. Porrata, E. Reay, S. Sankaran-Walters, C. C. Ignacio, T. Russell, S. K. Pillai, D. J. Looney, and S. Dandekar. 2010. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6: e1000748.
39. Montecino-Rodriguez, E., and K. Dorshkind. 2012. B-1 B cell development in the fetus and adult. Immunity 36: 13-21.
40. Attanavanich, K., and J. F. Kearney. 2004. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 172: 803-811.
41. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153: 1990-1997.
42. Pillai, S., and A. Cariappa. 2009. The follicular versus marginal zone B lymphocyte cell fate decision. Nat. Rev. Immunol. 9: 767-777.
43. Moran, S. T., A. Cariappa, H. Liu, B. Muir, D. Sgroi, C. Boboila, and S. Pillai. 2007. Synergism between NF-kappa B1/p50 and Notch2 during the development of marginal zone B lymphocytes. J. Immunol. 179: 195-200.
44. Cyster, J. G., and S. R. Schwab. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30: 69-94.
45. Enzler, T., G. Bonizzi, G. J. Silverman, D. C. Otero, G. F. Widhopf, A. Anzelon-Mills, R. C. Rickert, and M. Karin. 2006. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25: 403-415.
46. Lu, T. T., and J. G. Cyster. 2002. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 297: 409-412.
47. Hobeika, E., S. Thiemann, B. Storch, H. Jumaa, P. J. Nielsen, R. Pelanda, and M. Reth. 2006. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl. Acad. Sci. USA 103: 13789-13794.
48. Pillai, S., A. Cariappa, and S. T. Moran. 2005. Marginal zone B cells. Annu. Rev. Immunol. 23: 161-196.
49. Martin, F., and J. F. Kearney. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2: 323-335.